170 related articles for article (PubMed ID: 36241231)
21. Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.
Kim SJ; Kim JH; Yang B; Jeong JS; Lee SW
Mol Ther; 2017 Feb; 25(2):356-367. PubMed ID: 28153088
[TBL] [Abstract][Full Text] [Related]
22. 4-Acetyl-Antroquinonol B Improves the Sensitization of Cetuximab on Both Kras Mutant and Wild Type Colorectal Cancer by Modulating the Expression of Ras/Raf/miR-193a-3p Signaling Axis.
Chu YC; Tsai TY; Yadav VK; Deng L; Huang CC; Tzeng YM; Yeh CT; Chen MY
Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299137
[TBL] [Abstract][Full Text] [Related]
23. T cell epitopes encompassing the mutational hot spot position 61 of p21 ras. Promiscuity in ras peptide binding to HLA.
Gedde-Dahl T; Spurkland A; Fossum B; Wittinghofer A; Thorsby E; Gaudernack G
Eur J Immunol; 1994 Feb; 24(2):410-4. PubMed ID: 7507844
[TBL] [Abstract][Full Text] [Related]
24. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid Cancer Antigens Calcitonin, CEA, and RET M918T.
Erickson TA; Shih YP; Fass J; Jang M; Tran E
Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
[No Abstract] [Full Text] [Related]
25. A novel cell line generated using the CRISPR/Cas9 technology as universal quality control material for KRAS G12V mutation testing.
Jia S; Zhang R; Lin G; Peng R; Gao P; Han Y; Fu Y; Ding J; Wu Q; Zhang K; Xie J; Li J
J Clin Lab Anal; 2018 Jun; 32(5):e22391. PubMed ID: 29380513
[TBL] [Abstract][Full Text] [Related]
26. Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.
Wright KM; DiNapoli SR; Miller MS; Aitana Azurmendi P; Zhao X; Yu Z; Chakrabarti M; Shi W; Douglass J; Hwang MS; Hsiue EH; Mog BJ; Pearlman AH; Paul S; Konig MF; Pardoll DM; Bettegowda C; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S; Gabelli SB
Nat Commun; 2023 Aug; 14(1):5063. PubMed ID: 37604828
[TBL] [Abstract][Full Text] [Related]
27. Commentary: An
Beer I
Front Immunol; 2021; 12():523906. PubMed ID: 34326832
[No Abstract] [Full Text] [Related]
28. Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.
Cheng H; Luo G; Jin K; Fan Z; Huang Q; Gong Y; Xu J; Yu X; Liu C
Cancer Med; 2020 Mar; 9(6):2153-2159. PubMed ID: 32017404
[TBL] [Abstract][Full Text] [Related]
29. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
[TBL] [Abstract][Full Text] [Related]
30. Point mutation screening of tumor neoantigens and peptide-induced specific cytotoxic T lymphocytes using The Cancer Genome Atlas database.
Wu W; Chen Y; Huang L; Li W; Tao C; Shen H
Oncol Lett; 2020 Nov; 20(5):123. PubMed ID: 32934692
[TBL] [Abstract][Full Text] [Related]
31. Highly specific detection of KRAS single nucleotide polymorphism by asymmetric PCR/SERS assay.
Lyu N; Rajendran VK; Li J; Engel A; Molloy MP; Wang Y
Analyst; 2021 Sep; 146(18):5714-5721. PubMed ID: 34515700
[TBL] [Abstract][Full Text] [Related]
32. TCR-mimic antibody-drug conjugates targeting intracellular tumor-specific mutant antigen KRAS G12V mutation.
Shen Y; Wei X; Jin S; Wu Y; Zhao W; Xu Y; Pan L; Zhou Z; Chen S
Asian J Pharm Sci; 2020 Nov; 15(6):777-785. PubMed ID: 33363632
[TBL] [Abstract][Full Text] [Related]
33. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
34. Mutant Hras(G12V) and Kras(G12D) have overlapping, but non-identical effects on hepatocyte growth and transformation frequency in transgenic mice.
Figueiredo ML; Stein TJ; Jochem A; Sandgren EP
Liver Int; 2012 Apr; 32(4):582-91. PubMed ID: 22221894
[TBL] [Abstract][Full Text] [Related]
35. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human.
Sun Q; Zhang X; Wang L; Gao X; Xiong Y; Liu L; Wei F; Yang L; Ren X
Cell Death Dis; 2019 Jun; 10(7):475. PubMed ID: 31209257
[TBL] [Abstract][Full Text] [Related]
36. [A method of screening highly common neoantigens with immunogenicity in colorectal cancer based on public somatic mutation library].
Qin LL; Li YJ; Liang ZR; Dai L; Li WH; Chen C; Huang YL; Zhang L; Liu SM; Qiu S; Ge YP; Peng WT; Lin XX; Zhang XQ; Dong X; Li B
Yi Chuan; 2020 Jun; 42(6):599-612. PubMed ID: 32694118
[TBL] [Abstract][Full Text] [Related]
37. Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes.
Tsuji T; Yasukawa M; Matsuzaki J; Ohkuri T; Chamoto K; Wakita D; Azuma T; Niiya H; Miyoshi H; Kuzushima K; Oka Y; Sugiyama H; Ikeda H; Nishimura T
Blood; 2005 Jul; 106(2):470-6. PubMed ID: 15790789
[TBL] [Abstract][Full Text] [Related]
38. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.
Bear AS; Blanchard T; Cesare J; Ford MJ; Richman LP; Xu C; Baroja ML; McCuaig S; Costeas C; Gabunia K; Scholler J; Posey AD; O'Hara MH; Smole A; Powell DJ; Garcia BA; Vonderheide RH; Linette GP; Carreno BM
Nat Commun; 2021 Jul; 12(1):4365. PubMed ID: 34272369
[TBL] [Abstract][Full Text] [Related]
39. Response: Commentary: An
Mishto M; Rodriguez-Hernandez G; Neefjes J; Urlaub H; Liepe J
Front Immunol; 2021; 12():679836. PubMed ID: 34326838
[No Abstract] [Full Text] [Related]
40. Incongruity between T cell receptor recognition of breast cancer hotspot mutations ESR1 Y537S and D538G following exogenous peptide loading versus endogenous antigen processing.
Shafer P; Leung WK; Woods M; Choi JM; Rodriguez-Plata CM; Maknojia A; Mosquera A; Somes LK; Joubert J; Manliguez A; Ranjan R; Burt B; Lee HS; Zhang B; Fuqua S; Rooney C; Leen AM; Hoyos V
Cytotherapy; 2024 Mar; 26(3):266-275. PubMed ID: 38231165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
